Equol and vascular function in women with CKD
Official title: Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD
Run by University of Colorado, Denver · NCT07194590 · Data updated 2026-11-12
This study tests whether taking equol for 12 weeks improves vascular function in postmenopausal women with chronic kidney disease.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years and up |
| Sex | Women only |
| Enrollment | 74 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Status | Recruiting |
| Started | February 19, 2026 |
| Main results expected | November 30, 2030 |
| Study ends | November 30, 2030 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT07194590 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Postmenopausal women aged 50 or older with CKD stage 3–4 (eGFR 15–59), stable renal function, and low soy intake.
✕Probably not a fit
Individuals with advanced CKD requiring dialysis, uncontrolled hypertension, current hormone therapy use, or soy intolerance may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 randomized trial will evaluate the effect of oral equol versus placebo on vascular function in postmenopausal women with CKD stages 3–4. The study targets improvements in measures of endothelial function and arterial stiffness, areas disrupted by CKD and reduced sex hormone exposure. Participants will be adults aged 50 and older with stable kidney function, low soy intake, and no recent hormone therapy. The trial is sponsored by the University of Colorado, Anschutz Medical Campus, with NHLBI collaboration, and is conducted at a single site in Aurora, Colorado. Safety monitoring will screen for liver enzyme elevations and other adverse events related to soy-derived products.
Why it matters
Potential benefit: If successful, equol could improve vascular function and potentially reduce cardiovascular risk in women with CKD.
How similar studies have gone: Previous work suggests sex-hormone–related vascular effects are modifiable, but this exact equol approach in CKD women is novel and needs evidence of benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Postmenopausal women * Aged ≥50 years * CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL/min/1.73m2; stable renal function in the past 3 months) * Low habitual intake of soy (soy-related food intake \< 2 times per week assessed by Soy-Specific Food Frequency Questionnaire) * Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study * Ability to provide informed consent. Exclusion Criteria: * Patients with advanced CKD requiring chronic dialysis * Uncontrolled hypertension in CKD group (BP \>140/90 mmHg) * Use of any hormone replacement therapy * Allergy and/or intolerance to soy or soy-based products * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U/L; ALT: 52 U/L; total bilirubin: 1.3 mg/dL) * History of breast cancer * Significant co-morbid conditions with a life expectancy of \< 1 year * Current tobacco or nicotine use or history of use in the last 12 months * History of kidney transplant * History of severe congestive heart failure (i.e., ejection fraction \<35%) * History of hospitalization within the last month * Immunosuppressant agents taken in the past 12 months * Known malignancy
Where it's running
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States Recruiting
Study contacts
- Study coordinator: Ester Oh, PhD
- Email: ester.oh@cuanschutz.edu
- Phone: 303-724-3765
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Synbiotic Therapy for Kidney Function in CKD Stage III-IV
This study tests whether a synbiotic (probiotics plus prebiotics) can improve kidney function in adults with non-dialysis CKD stage 3-4 compared with a placebo.
-
Overnight Temperature Regulation to Test Gut Health, Inflammation, and Circadian Rhythms
This study tests whether two weeks of using the Eight Sleep Pod at night can improve gut bacteria balance, lower inflammation, and strengthen daily temperature and blood pressure rhythms in postmenopausal women and age-matched men with poor sleep.
-
Ashwagandha with resistance training to boost strength and stress markers
This 12-week study tests whether taking ASHWAGANDHA along with regular resistance training helps healthy, trained men see improvements in strength, stress levels, sleep, and cognitive function compared with a placebo.
-
Automated Non-Invasive Blood Pressure: Tracking Blood Pressure Changes Using SpO2 Data
This study tests an algorithm that estimates blood pressure changes using data from an SpO2 sensor in patients in the OR, PACU, or ICU who already have invasive BP measured as part of standard care.
-
Sports-based cognitive therapy for kids with attention/behavior challenges
The study tests a sports-based cognitive therapy program to see if it improves attention, memory, and behavior in school-aged children with mild to moderate difficulties.
-
AI-guided prediction of blood pressure changes in spinal cord injury using perfusion index during a cool-temperature test
This study tests whether perfusion index can reliably predict changes in systolic blood pressure in people with spinal cord injury during a controlled cool temperature challenge.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.